In this webinar designed for patients and caregivers, two patients share their experiences receiving immunotherapy and answer viewer questions.
Dr. John Bell of the University of Ottawa and the Ontario Institute for Cancer Research discussses strategies that re-program viruses so that they selectively infect and kill cancer cells while leaving healthy cells and tissues unharmed.
In this webinar designed for patients and caregivers, an oncologist and patient share their experiences with immunotherapy and answer viewer questions.
Patrick Meins of EmergingMed will answer common questions around cancer clinical trials including trial definitions, eligibility criteria, and how to search for the right one.
Dr. James P. Allison of MD Anderson discusses how some proteins in immune cells act as "brakes" on the immune system response and how checkpoint inhibitors can be used to “release the brakes,” allowing a stronger immune attack against cancer.
Dr. Jedd D. Wolchok of Memorial Sloan Kettering Cancer Center discusses the latest developments in patient care including: checkpoint blockade, cancer vaccines, combination therapies, CAR T cell therapy, T cell receptor therapies, and neoantigens.
Dr. John B. Liao of the University of Washington discusses the immunotherapy landscape for patients with ovarian cancer.
Dr. Dustin A. Deming of the University of Wisconsin Carbone Cancer Center discusses the most effective immunotherapies currently available to patients with stomach, gastrointestinal (GI), and colorectal (CRC) cancers.
Dr. Robert D. Schreiber of of Washington University School of Medicine in St. Louis discusses how advances in our understanding of genomics have enabled doctors to identify the mutations driving individual tumors.
Dr. Hearn Jay Cho of the Mt. Sinai School of Medicine discusses the latest research and developments in cancer immunotherapy for leukemia, lymphoma, and multiple myeloma.
Dr. Haidong Dong of the Mayo Clinic discusses the role biomarkers play in making treatment decisions and delves into the latest research to identify new biomarkers.
Dr. Marie Bleakley of the University of Washington School of Medicine and Seattle Children's Hospital discusses the latest research and developments in immunotherapy for childhood (pediatric) cancers.
In this webinar designed for patients and caregivers, three cancer survivors share their experiences receiving immunotherapy in clinical trials and answer viewer questions.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Day 4 at AACR18 was a special day for CRI’s Dr. Antoni Ribas, and highlighted his and others’ efforts to overcome resistance to PD-1 therapy as well as insights into the role of dendritic cells.
Day 3 of AACR18 highlighted potentially “practice-changing” immunotherapy breakthroughs in lung cancer, and insights into the factors governing immunotherapy’s effectiveness in several other cancer types